UK Markets close in 1 hr 15 mins

Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
92.82+0.93 (+1.01%)
As of 10:15AM EDT. Market open.
Sign in to post a message.
  • B
    Brent
    More price target upgrades over $100 this morning. Getting interesting.
  • W
    William
    Up again today in a red tape. Good news keeps rolling in. SGEN buyout could hurt price and earnings in short term but 2 years out it gets accretive according to recently published analysis. Long and strong! Just wish I bought more at 82.
  • m
    marco
    $VBIV conversation
    Could $MRK buyout $VBIV in 2022?
    VBI Vaccines is set to become a leader in the areas of Hep-B + GBM. Their COVID pipeline coming up for VBI-2905 data will validate further NRC & CEPI funding.

    This plausible speculation has a lot of extensive DD done to come to the conclusion that Merck will either buyout $VBIV or do a major partnership for theor Hep-B & oncology pipeline.

    CEO remarks last Call:

    "But we're really excited about the TRIPLE COMBINATION when it reads out in the second half of this year through our colleagues at Brii and what informs for the rest of the world. We VBI has retained Ex-China rights to this. Once we have some data, if it is successful, touch-wood, then WE WILL HAVE SOME INTERESTING DISCUSSIONS WITH SOME OTHER PLAYERS WHO LOOK TO MAKE SIGNIFICANT MOVES IN THIS FIELD FOR THE REST OF WORLD RIGHTS."

    https://www.reddit.com/r/VBIV/comments/tp2wi3/merck_potential_buyout_candidate_for_vbiv_dd_by/
  • r
    ridingbreakouts
    MRK $125 min to $150 within 12 months fundamental and technical dream w a 3% yield. Beat and raise quarter powerhouse. P/E of 18-20 makes MRK a bargain sub $90 today
  • C
    Cured
    $SLS conversation
    $bmy $mrk b like
    Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is 28 Weeks
  • K
    Khalid
    Merck & Company's upcoming ex-dividend date is on Jun 13, 2022. Merck & Company shareholders who own MRK stock before this date will receive Merck & Company's next dividend payment of $0.69 per share 🎉
  • C
    C
    WATCH for possible breakout above 94.37, no resistance in area just above.
    Type: Continuation breakout from single resistance.
    Target: 99.14
    Stop: 91.40
  • r
    rich
    will drop to 80 soon
  • m
    mike
    what happened today
  • P
    P509$
    $SLS conversation
    Kind of deal I expect we'll see here $BMY is competing with $MRK - Gps gives both companies an effective therapy for Ovarian cancer.
    https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/
  • C
    Charlie
    BIG news for MRK. the stage #3 Metastasis news could be huge stock up over $100 this week
  • f
    fireundersmoke
    MRK needs some help to compete. News out today 6/4/22 (VTVT) and their TTP399 going for FDA 3 trials soon, People with Type 1 Diabetes may get an oral drug soon. MRK tried before to get in this market, MRK needs to take a look for us shareholders.
  • W
    William
    Article out today says MRK sniffing around Seagen...
  • C
    Cured
    $SLS conversation
    A reminder, $mrk Has no other trials for these Platinum Refractor patients, Keytruda ineffective alone, and not one other Merck Partnership is in trial - Gps +Keytruda has a 54% Disease Control rate and a median Os yet to be reached, but already longer than all other therapies.
    All enrolled patients were resistant to standard of care platinum-based therapy and 78.5 percent of evaluable patients were refractory to or had failed their first- or second-line therapies with 21.5 percent having failed three or more lines of therapy, including one patient who failed five previous lines of therapy. Of the 15 patients, 13 received at least three doses of GPS, the last of which was in combination with pembrolizumab, and were evaluable for response outcomes.

    Summary of Top-Line Clinical Data
    An ad hoc analysis of clinical outcomes in this cohort shows a disease control rate (DCR), the sum of overall response rate and rate of stable disease, of 53.9 percent at a median follow-up of 43.1 weeks. In a checkpoint inhibitor single agent study in a similar platinum-resistant ovarian cancer patient population treated with a checkpoint inhibitor alone, the observed DCR was 37.2 percent, consistent with a DCR rate increase of 45 percent in the GPS combination with pembrolizumab over that seen for checkpoint inhibitors alone.
    Median progression-free survival (PFS) was 12 weeks compared to 8.4 weeks for checkpoint inhibitors alone seen in studies with similar patient populations, a 43 percent increase in the GPS combination with pembrolizumab. Patients with fewer previous lines of chemotherapy experienced a more favorable median PFS than those with more than two previous lines: for patients with two or fewer previous lines of therapy treated with GPS in combination with pembrolizumab, median PFS was 24 weeks.
    With 43.1 weeks of follow-up the median overall surviva
  • S
    Stephens
    $SLS conversation
    Serious: If the DMC doesn't stop the P3 early for Efficacy and SLS isn't bought by $MRK or $BMY
    What will SLS' market value be when the FDA gets a look at the AML results? When is that?
    Lastly, when will the market begin to appreciate SLS shares in advance of that massively valuable inflection point?
  • C
    Cured
    $SLS conversation
    $MRK Gps Keytruda Ovarian Cancer last update "Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
    Avg Os with existing soc is 9/10 months
    “Based on these early data, it is encouraging to see the induction of WT1-specific T-cell immune responses with the administration of GPS in combination with pembrolizumab with a validated complex ex-vivo immune response assay on peripheral blood from patients with platinum-refractory metastatic ovarian cancer who had undergone numerous prior therapies,” Jeffrey S. Weber, MD, PhD, the deputy director of the Perlmutter Cancer Center at NYU Langone Health, and chair of SELLAS’ Scientific Advisory Board, added in the press release.
  • B
    Berlin 68
    $XBI conversation
    SLS diverging / up nicely, with shorts covering all what they sold the last couple weeks to hold it down, after great trial data with $MRK $BMY. SLS Is ripe for a squeeze.
  • D
    Dennis
    Great volume today 6/24, more than 2x the three month average
  • S
    Sigrid V
    Maybe Merck will have stock split. Google and Amazon are expected to split soon. I'd love it if Merck had a split.